DLEC1 Polyclonal Antibody

The cytogenetic location of DLEC1 (deleted in lung and esophageal cancer 1) is 3p21. , and it is located in a region that is commonly deleted in a variety of malignancies. Down-regulation of DLEC1 has been observed in several human cancers including lung, esophageal, renal tumors, and head and neck squamous cell carcinoma. In some cases, reduced expression of DLEC1 in tumor cells is a result of aberrant promoter methylation. Several alternatively spliced transcripts have been observed that contain disrupted coding regions and likely encode nonfunctional proteins.

The DLEC1 Polyclonal Antibody is a highly specific and sensitive antibody that has been designed to detect and quantify the expression of DLEC1 protein in various biological samples. This antibody has been extensively validated for use in a wide range of applications, including Western blotting, immunohistochemistry, and immunofluorescence.

The DLEC1 Polyclonal Antibody has been produced using high-quality materials and state-of-the-art techniques to ensure maximum specificity and sensitivity. It has been purified using a combination of protein A and protein G chromatography, and has been extensively characterized to ensure that it meets the highest standards of quality and performance.

This antibody is suitable for use in a variety of research applications, including cancer research, developmental biology, and immunology. It has been shown to be highly effective in detecting DLEC1 protein expression in a variety of cell lines and tissues, and has been used in numerous published studies.

Overall, the DLEC1 Polyclonal Antibody is a reliable and effective tool for researchers who are interested in studying the expression and function of DLEC1 protein in various biological systems. Its high specificity and sensitivity make it an ideal choice for a wide range of applications, and its extensive validation ensures that it will provide accurate and reproducible results.